Natick-based Boston Scientific, which holds more than 15,000 patents and makes 13,000 medical devices including heart pacemakers, is working hard to get its rhythm back. Fresh off positive first-quarter earnings and Food and Drug Administration approval of key devices, the $7.8 billion company, which specializes in cardiovascular aids such as drug-coated stents and defibrillators, is touting its “rejuvenated, revitalized product pipeline” and a three-pronged strategy for global expansion as it holds its annual shareholders meeting today.
